Phase II Trial of HRS-7450 Injection for Acute Ischemic Stroke Initiated by Fujian Shengdi
Fujian Shengdi Pharmaceutical has initiated Phase II clinical trial for HRS-7450 Injection targeting Acute Ischemic Stroke.
Company
Pharmaceutical intelligence for Fujian Shengdi Pharmaceutical with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.